Viral Hepatitis News

ISA Pharmaceuticals announced that the first patient has been treated in its first-in-human phase 1 trial of its novel immunotherapeutic agent intended as a “functional cure” for patients with chronic hepatitis B virus infection.

Global burden of hepatitis B virus is estimated to be 257.5 million individuals, according to recent data in Lancet Gastroenterology & Hepatology, which, although lower than current WHO estimates, falls short of 2030 elimination targets.

Researchers estimated that the introduction of generic medications for chronic hepatitis B virus infection could save Medicare Part D nearly $300 million annually from the cost of medication alone, according to data in Gastroenterology.

Maternal hepatitis B virus serostatus was not associated with pregnancy outcomes in infertile women in China who underwent freeze-thaw embryo transfer, according to data in JAMA Network Open.

On Friday, clinicians and researchers across the world recognized World Hepatitis Day as an opportunity to honor the “more than a million lives lost to hepatitis” every year and redouble national efforts to stop its spread.

Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.

Research demonstrated that hepatocellular carcinoma surveillance is cost-effective at a lower incidence threshold of 0.7% in virologically cured patients with hepatitis C virus, underscoring the need to update clinical guidelines.

The risk for hepatic decompensation and hepatocellular carcinoma remained constant after hepatitis C virus cure among patients with advanced chronic liver disease, underscoring the need for post-HCV risk stratification in the long term.

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.

Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.